(R)-N-(2-chloro-4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide

ID: ALA5286823

Max Phase: Preclinical

Molecular Formula: C13H14ClN3O2

Molecular Weight: 279.73

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)Nc1ccc(C2=NNC(=O)C[C@H]2C)cc1Cl

Standard InChI:  InChI=1S/C13H14ClN3O2/c1-7-5-12(19)16-17-13(7)9-3-4-11(10(14)6-9)15-8(2)18/h3-4,6-7H,5H2,1-2H3,(H,15,18)(H,16,19)/t7-/m1/s1

Standard InChI Key:  HPCQOMJDWMEKJA-SSDOTTSWSA-N

Molfile:  

 
     RDKit          2D

 19 20  0  0  0  0  0  0  0  0999 V2000
    5.3132  -18.9272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3121  -19.7522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0248  -20.1639    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7393  -19.7517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7364  -18.9235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0230  -18.5155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5992  -20.1629    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8870  -19.7511    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1742  -20.1618    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4488  -18.5118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1626  -18.9226    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.8715  -18.5122    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.8726  -17.6891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1587  -17.2782    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4437  -17.6905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5850  -17.2777    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.7300  -17.2811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8877  -18.9284    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.0246  -20.9866    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  2  7  1  0
  7  8  1  0
  8  9  1  0
 10 11  2  0
 10 15  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
  5 10  1  0
 13 16  2  0
 15 17  1  6
  8 18  2  0
  3 19  1  0
M  END

Alternative Forms

  1. Parent:

    ALA5286823

    ---

Associated Targets(Human)

SK-MEL3 (228 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A498 (42825 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HeLa (62764 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDE3A Tclin Phosphodiesterase 3A (3309 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDE3B Tclin Phosphodiesterase 3B (312 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 279.73Molecular Weight (Monoisotopic): 279.0775AlogP: 2.16#Rotatable Bonds: 2
Polar Surface Area: 70.56Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 11.74CX Basic pKa: 0.85CX LogP: 1.39CX LogD: 1.39
Aromatic Rings: 1Heavy Atoms: 19QED Weighted: 0.87Np Likeness Score: -1.16

References

1. Lewis TA, de Waal L, Wu X, Youngsaye W, Wengner A, Kopitz C, Lange M, Gradl S, Ellermann M, Lienau P, Schreiber SL, Greulich H, Meyerson M..  (2019)  Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.,  10  (11): [PMID:31749907] [10.1021/acsmedchemlett.9b00360]

Source